Emru U. Seli, MD, Assistant Professor and Director of the Third Party Reproductive Program at Yale University, discusses fertility preservation for women who are about to undergo treatment…
Charles E. Argoff, MD, Professor of Neurology and Director of the Comprehensive Pain Center, Albany Medical Center, describes new guidelines for pain management in geriatrics. The most reasonable…
NEW YORK (Reuters Health) – Postmenopausal women treated for osteoporosis with the selective estrogen receptor modulator lasofoxifene have a reduced risk of coronary heart disease events, researchers report…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to state-of-the-art adjuvant chemotherapy for stage II or III colon cancer does not improve disease-free survival, according…
NEW YORK (Reuters Health) – Rofecoxib used as adjuvant therapy does not improve survival or reduce recurrences in patients who have undergone surgery for colorectal cancer, according to…
NEW YORK (Reuters Health) – Adding interferon alpha-2b and megadose vitamins to treatment with intravesical BCG does not improve outcomes in patients with non-muscle invasive bladder cancer. In…
NEW YORK (Reuters Health) – When gynecologic surgery is performed laparoscopically, the occurrence of thromboembolism is quite rare, even in patients with gynecologic malignancy, researchers report in the…
NEW YORK (Reuters Health) – Men undergoing androgen deprivation therapy for prostate cancer halve their risk of vertebral fractures if they take the selective estrogen receptor modulator toremifene…
NEW YORK (Reuters Health) – A Canadian study has identified several readily available clinical factors that help determine the risk of fractures in men with prostate cancer undergoing…
NEW YORK (Reuters Health) – Among men who’ve had a negative prostate biopsy, the velocity of increasing prostate specific antigen (PSA) levels is not helpful in deciding whether…
